Ascendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024. In the quarter to June 2026, revenue grew 119.9%, EPS grew 612.3%, free cash flow grew 2,335.9% and total debt fell 41.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow ASND
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
944.41 | 670.43 | 696.99 | 630.14 |
+8 more quarters Free account |
Receivables |
260.56 | 230.11 | 178.42 | 172.12 | |
Inventory |
361.11 | 367.91 | 341.15 | 353.03 | |
Total current assets |
1,616.63 | 1,313.59 | 1,254.71 | 1,189.68 | |
Property, Plant, Equpment (Net) |
157.76 | 159.08 | 165.73 | 118.95 | |
Long-Term Investments |
35.44 | 27.57 | 36.80 | 33.08 | |
Long-term receivables |
30.80 | 32.03 | 12.30 | 3.69 | |
Goodwill and Intangible Assets (Total) |
4.28 | 4.32 | 4.20 | 4.37 | |
Long Term Assets (Tax, Deferred) |
813.05 | 808.05 | — | — | |
Total non-current assets |
1,041.33 | 1,031.05 | 219.02 | 160.10 | |
Total Assets |
2,657.96 | 2,344.64 | 1,473.73 | 1,349.79 | |
Accounts Payable |
120.83 | 91.98 | 102.57 | 91.88 | |
Current Part of Debt |
76.08 | 597.56 | 550.46 | 563.74 | |
Current Part of Taxes to Pay |
14.72 | 9.14 | 7.27 | 1.88 | |
Other current liabilities |
328.90 | 620.09 | 549.61 | 495.60 | |
Total current liabilities |
540.52 | 1,318.76 | 1,209.91 | 1,153.10 | |
Long Term Debt (Total) |
447.22 | 451.90 | 435.88 | 387.34 | |
Long Term Tax Liability (Deferred) |
— | — | 10.89 | 12.02 | |
Non-current Liabilities (Other) |
— | 2.85 | 1.27 | 0.81 | |
Total non-current liabilities |
447.22 | 454.75 | 448.03 | 400.16 | |
Total liabilities |
987.75 | 1,773.51 | 1,657.94 | 1,553.26 | |
Additional Paid In Capital |
3,836.91 | 2,999.32 | 2,863.66 | 2,940.68 | |
Common Stock (Net) |
10.33 | 9.81 | 9.42 | 9.68 | |
Retained Earnings |
(2,184.11) | (2,439.49) | (3,055.22) | (3,152.27) | |
Treasury Stock |
0.08 | 0.04 | 0.09 | 0.09 | |
Shareholders Equity (Other) |
7.16 | 1.53 | (1.99) | (1.48) | |
Common Equity (Total) |
1,670.21 | 571.12 | (184.22) | (203.48) | |
Shareholders Equity (Total) |
1,670.21 | 571.12 | (184.22) | (203.48) | |
Shareholders Equity and Liabilities (Total) |
2,657.96 | 2,344.64 | 1,473.73 | 1,349.79 | |
Shares (Common) |
65.67 | 62.11 | 61.98 | 61.10 | |
Shareholders Equity (Tangible) |
1,665.93 | 566.81 | (188.41) | (207.85) | |
Net Debt |
(421.11) | 379.03 | 289.35 | 320.93 | |
Total Debt |
523.30 | 1,049.46 | 986.34 | 951.08 |